Immatics (NASDAQ:IMTX) Shares Gap Down to $9.43

Immatics (NASDAQ:IMTXGet Rating)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $9.43, but opened at $9.22. Immatics shares last traded at $9.22, with a volume of 4 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IMTX shares. Chardan Capital lowered their price objective on Immatics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. SVB Leerink lifted their price objective on Immatics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Friday, June 3rd.

Immatics Stock Performance

The firm has a market cap of $569.33 million, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 2.60 and a beta of 0.30. The stock has a fifty day simple moving average of $11.32 and a 200 day simple moving average of $9.09.

Immatics (NASDAQ:IMTXGet Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.36). The business had revenue of $18.19 million during the quarter, compared to the consensus estimate of $42.27 million. Immatics had a return on equity of 36.11% and a net margin of 18.88%. Research analysts predict that Immatics will post 0.37 earnings per share for the current year.

Institutional Trading of Immatics

A number of institutional investors and hedge funds have recently modified their holdings of IMTX. GSA Capital Partners LLP bought a new stake in shares of Immatics in the 4th quarter worth $266,000. Sofinnova Investments Inc. grew its holdings in shares of Immatics by 114.7% in the fourth quarter. Sofinnova Investments Inc. now owns 1,026,623 shares of the company’s stock worth $13,798,000 after acquiring an additional 548,407 shares during the period. Woodline Partners LP grew its holdings in shares of Immatics by 22.7% in the fourth quarter. Woodline Partners LP now owns 743,490 shares of the company’s stock worth $9,993,000 after acquiring an additional 137,570 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Immatics by 150.5% in the first quarter. JPMorgan Chase & Co. now owns 202,640 shares of the company’s stock worth $1,619,000 after acquiring an additional 121,754 shares during the period. Finally, BlackRock Inc. bought a new stake in shares of Immatics in the first quarter worth $27,000. Institutional investors own 34.12% of the company’s stock.

About Immatics

(Get Rating)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Featured Stories

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.